Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
By John P. A. Ioannidis, S. Evans, Peter Gtzsche, R. O'neill, Douglas G. Altman, K. F. Schulz, David Moher. Annals of Internal Medicine, 2004
1,406 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/a227b1f4bf8aade552f933fa1055b14080ce33d2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
- Douglas G. Altman
- David Moher
- K. F. Schulz
- Matthias Egger
- Stuart J. Pocock
- Diana Elbourne
- P. Gøtzsche
- Gunther Eysenbach
In Statistics and Probability
- Douglas G. Altman
- David Moher
- K. F. Schulz
- Matthias Egger
- P. Gøtzsche
- Stuart J. Pocock
- Diana Elbourne
- E. von Elm
Citations in the corpus
- Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. (2006, methodology): “The current recommendations add to recent extensions to cluster randomized trials,(66) and the reporting of harms.(4) Further extensions are in preparation.”
- [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. (2008, methodology): “Four extensions are now available for the CONSORT statement [21 e 24].”
- Korean translation of the CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials (2014, neutral): “항목 19 (위해) – 위해와 관련된 CONSORT에 대한 참조를 포함하였다 [28].”
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, background): “Further well designed and rigorously executed randomized trials that measure and properly report [252, 253] patientimportant outcomes are needed, as are studies of patients identified to have an eosinophilic phenotype.”